CDK4 and neoplasm: However, while anti-CDK4 monotherapy is associated with limited response, preclinical models have suggested overexpression of CDK4 may lead to induced expression of PD-L1 by tumor cells, paving the way to employ possible combination targeted therapy regimens [53].